SOURCE: Skystar Bio-Pharmaceutical Company

Skystar Bio-Pharmaceutical Company

February 11, 2010 07:00 ET

Skystar Included in New York Pacific Capital China SME Growth Index

XI'AN, CHINA--(Marketwire - February 11, 2010) - Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based producer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today announced the Company's inclusion in the New York Pacific Capital (NYPC) China Small and Medium Enterprises (SME) Growth Index.

The index, which launched on January 1, 2010, is currently composed of 58 Chinese companies with market capitalizations ranging from $50 million to $1.5 billion. The index is designed to measure and monitor the performance of high-growth small- and mid-cap Chinese companies traded on exchanges outside of mainland China. The 58 companies included at launch were selected from 319 companies listed on exchanges in the United States, Hong Kong, Canada, Europe, Singapore, Japan and Korea.

The companies that were initially included had revenue growth rates at least double the China GDP growth rate along with positive net margin, daily trading value over $500,000, and a minimum public float of 30% of the total outstanding shares.

"We are very pleased to be included in this index," said Weibing Lu, Skystar's Chairman and Chief Executive Officer. "We believe Skystar's inclusion in the index will assist in gaining further investor awareness among China-focused investors worldwide."

About NYPC China SME Growth Index

The U.S. dollar denominated NYPC China SME Growth Index is weighted by market capitalization, with a range from $50 million to $1.5 billion for initial portfolio formation and eligibility. The index currently consists of 58 fast growing Chinese companies from nine sectors including consumer discretionary, industrials, IT, consumer staples, healthcare, energy, financials, utilities, and telecommunication services. The small cap ranges up to $1 billion and account for 77% while the mid caps of $1 billion to $1.5 billion account for 23%. The component companies have revenue growth of at least double the China GDP growth rate with positive net margin, daily trading value over $500,000, and at least 30% public float of outstanding shares. The Index was created, calculated, and will be maintained by New York Pacific Capital Ltd, whose index committee serves as the index administrator for review and compliance of index-eligible companies.

The index will be rebalanced by the index committee semi-annually in January and July. The index will also be reviewed on an ongoing basis to account for corporate actions such as mergers, new share issuances, de-listings, etc. Any changes to the methodology will be publicly disclosed prior to implementation within ten (10) trading days.

About NYPC

NYPC is a China-focused, global merchant bank that provides strategic advisory services and direct investments for NYPC's private and public clients around the world. NYPC's team has over a decade of successful experience as investment bankers and institutional investors. NYPC provides flexible capital solutions that fulfill a company's needs in their different stages of development and enable the companies to maximize their long-term enterprise value. More information can be found at

About Skystar Bio-Pharmaceutical Company

Skystar is a China-based developer and distributor of veterinary healthcare and medical care products. Skystar has four product lines (veterinary medicines, micro-organisms, vaccines and feed additives) and over 170 products. Skystar has formed strategic sales distribution networks covering 29 provinces throughout China. For additional information, please visit

To be added to the Skystar's email distribution for future news releases, please send your request to

Forward-looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

Contact Information

  • Contacts
    The Piacente Group, Inc. (Investor Relations Counsel)
    Brandi Floberg
    (212) 481-2050
    Email Contact

    Skystar Bio-Pharmaceutical Company
    Scott Cramer
    Director - U.S. Representative
    (407) 645-4433
    Email Contact